MENU
+Compare
CUE
Stock ticker: NASDAQ
AS OF
Dec 18, 04:57 PM (EDT)
Price
$1.07
Change
+$0.01 (+0.94%)
Capitalization
67.15M

CUE Cue Biopharma Forecast, Technical & Fundamental Analysis

a developer of biopharmaceuticals

Industry Biotechnology
CUE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
a Summary for CUE with price predictions
Dec 17, 2024

CUE sees its 50-day moving average cross bullishly above its 200-day moving average

The 50-day moving average for CUE moved above the 200-day moving average on December 10, 2024. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where CUE advanced for three days, in of 233 cases, the price rose further within the following month. The odds of a continued upward trend are .

CUE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on December 12, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on CUE as a result. In of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

CUE moved below its 50-day moving average on November 18, 2024 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for CUE crossed bearishly below the 50-day moving average on November 26, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CUE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for CUE entered a downward trend on December 17, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.547) is normal, around the industry mean (14.664). P/E Ratio (0.000) is within average values for comparable stocks, (87.689). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.783). CUE has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (5.299) is also within normal values, averaging (260.687).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CUE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CUE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
CUE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

CUE is expected to report earnings to fall 49.41% to -8 cents per share on March 12

Cue Biopharma CUE Stock Earnings Reports
Q4'24
Est.
$-0.09
Q3'24
Beat
by $0.01
Q2'24
Beat
by $0.08
Q1'24
Beat
by $0.04
Q4'23
Est.
$-0.28
The last earnings report on November 15 showed earnings per share of -17 cents, beating the estimate of -18 cents. With 290.76K shares outstanding, the current market capitalization sits at 67.15M.
A.I. Advisor
published General Information

General Information

a developer of biopharmaceuticals

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
40 Guest Street
Phone
+1 617 949-2680
Employees
53
Web
https://www.cuebiopharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CSV41.080.27
+0.66%
Carriage Services
VRTX469.241.15
+0.25%
Vertex Pharmaceuticals
SPHR38.01-0.04
-0.11%
Sphere Entertainment Co
CACC490.74-5.45
-1.10%
Credit Acceptance Corp
VRCA0.70-0.02
-2.51%
Verrica Pharmaceuticals

CUE and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, CUE has been loosely correlated with DNLI. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if CUE jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CUE
1D Price
Change %
CUE100%
+3.92%
DNLI - CUE
39%
Loosely correlated
-0.30%
VCYT - CUE
36%
Loosely correlated
-2.52%
AXON - CUE
33%
Loosely correlated
-2.09%
AMRN - CUE
32%
Poorly correlated
-0.80%
ARRY - CUE
31%
Poorly correlated
+6.01%
More